

For the Examiner's convenience, a complete claim set of the currently pending claims is also submitted herewith.

1. (as filed) A composition comprising an inositolphosphoglycan (IPG) or an IPG synthetic analogue and ribose.

2. (as filed) The composition of claim 1 wherein the IPG is a P-type IPG.

3. (as filed) The composition of claim 1 wherein the synthetic analogue is a P-type IPG synthetic analogue.

C1
4. (amended) The composition of claim 1, further comprising adenosine or purine, or a nucleotide precursor thereof.

C2
5. (twice amended) The composition of claim 1 or 2, wherein the composition is a liquid composition.

6. (twice amended) The composition of claim 1 or 2, wherein the composition is a powder or concentrate from which a liquid composition can be prepared.

C3
7. (amended) The composition of claim 1 or 2, further comprising a pharmaceutically acceptable excipient.

C4
8. (twice amended) A method of preparing a medicament for the treatment or prevention of an ischaemic-reperfusion injury, the method comprising:
providing an inositolphosphoglycan (IPG) or an IPG synthetic analogue and ribose in a pharmaceutically acceptable excipient.

C5
9. ^{twice}(amended) The method of claim 8, wherein the IPG is a P-type IPG.

10. ^{twice}(amended) The method of claim 8, wherein the synthetic analogue is a P-type IPG synthetic analogue.

C6
11. (twice amended) The method of claim 8, wherein the ischaemic-reperfusion injury arises from myocardial infarct, surgery or stroke.

C6
corrd

12. (twice amended) The method of claim 11, wherein the surgery is open heart surgery, organ transplantation surgery, or heart or lung bypass surgery.

13. (twice amended) The method of claim 8, wherein the ischaemic-reperfusion injury results in apoptosis.

C7

14. (thrice amended) The method of claim 8, wherein the medicament further comprises one or more of:

- (a) adenosine or purine or a precursor thereof;
- (b) nicotinamide or derivatives thereof;
- (c) a Ca^{2+} ion uptake inhibitor;
- (d) a cardioplegic solution;
- (e) means to maintain the glutathione system, such as glutathione peroxidase and the reduced form of glutathione (GSH); and,
- (f) an endothelin inhibitor.

15. (as filed) An in vitro method for preserving an organ for transplantation, the method comprising contacting the organ with a composition of claim 1.

16. (as filed) The method of claim 15 wherein the composition is perfused through the organ.

17. (as filed) The method of claim 15 wherein the organ is stored in the composition prior to transplantation.

C8

18. (amended) A method of reducing loss of cellular ATP, the method comprising:
administering a composition comprising an inositolphosphoglycan (IPG) or an IPG synthetic analogue and ribose to a cell in a dose sufficient to prevent or reduce the loss of cellular ATP.

19. (new) The method of claim 18, wherein the IPG is a P-type IPG.

20. (new) The method of claim 18, wherein the synthetic analogue is a P-type IPG synthetic analogue.